Your browser doesn't support javascript.
loading
Visceral leishmaniasis and HIV coinfection: current perspectives
Lindoso, José Ângelo Lauletta; Moreira, Carlos Henrique Valente; Cunha, Mirella Alves; Queiróz, Igor Thiago.
Afiliação
  • Lindoso, José Ângelo Lauletta; Secretaria de Estado da Saúde. São Paulo. Instituto de Infectologia Emílio Ribas. São Paulo. BR
  • Moreira, Carlos Henrique Valente; Secretaria de Estado da Saúde. São Paulo. Instituto de Infectologia Emílio Ribas. São Paulo. BR
  • Cunha, Mirella Alves; Universidade Federal do Rio Grande do Norte. Natal. BR
  • Queiróz, Igor Thiago; Universidade Potiguar (UnP). Natal. BR
HIV AIDS (Auckl) ; 10: 193-201, Oct. 2018. tab
Article em En | SES-SP, SESSP-IIERPROD, SES-SP | ID: biblio-1021385
Biblioteca responsável: BR31.1
Localização: BR31.1; 2018_P-043
ABSTRACT
Visceral leishmaniasis (VL) is caused by Leishmania donovani and Leishmania infantum. The burden of VL is concentrated in tropical and subtropical areas; however, HIV infection has spread VL over a hyperendemic area. Several outcomes are observed as a result of VL-HIV coinfection. Impacts are observed in immunopathogenesis, clinical manifestation, diagnosis, and therapeutic response. Concerning clinical manifestation, typical and unusual manifestation has been observed during active VL in HIV-infected patient, as well as alteration in immunoresponse, inducing greater immunosuppression by low CD4 T-lymphocyte count or even by induction of immunoactivation, with cell senescence. Serological diagnosis of VL in the HIV-infected is poor, due to low humoral response, characterized by antibody production, so parasitological methods are more recommended. Another important and even more challenging point is the definition of the best therapeutic regimen for VL in HIV-coinfected patients, because in this population there is greater failure and consequently higher mortality. The challenge of better understanding immunopathogenesis in order to obtain more effective therapies is one of the crucial points to be developed. The combination of drugs and the use of secondary prophylaxis associated with highly active antiretroviral therapy may be the best tool for treatment of HIV coinfection. Some derivatives from natural sources have action against Leishmania; however, studies have been limited to in vitro evaluation, without clinical trials
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IIERPROD Assunto principal: Infecções por HIV / Anfotericina B / Terapia Combinada / Leishmaniose Visceral Limite: Humans Idioma: En Revista: HIV AIDS (Auckl) Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IIERPROD Assunto principal: Infecções por HIV / Anfotericina B / Terapia Combinada / Leishmaniose Visceral Limite: Humans Idioma: En Revista: HIV AIDS (Auckl) Ano de publicação: 2018 Tipo de documento: Article